hypertonic saline
Recently Published Documents


TOTAL DOCUMENTS

2853
(FIVE YEARS 344)

H-INDEX

84
(FIVE YEARS 6)

2022 ◽  
Vol 8 ◽  
Author(s):  
Chengchen Han ◽  
Fan Yang ◽  
Shengli Guo ◽  
Jianning Zhang

Background: We performed a meta-analysis to evaluate the effect of hypertonic saline compared to mannitol for the management of elevated intracranial pressure in traumatic brain injury.Methods: A systematic literature search up to July 2021 was performed and 17 studies included 1,392 subjects with traumatic brain injury at the start of the study; 708 of them were administered hypertonic saline and 684 were given mannitol. They were reporting relationships between the effects of hypertonic saline compared to mannitol for the management of elevated intracranial pressure in traumatic brain injury. We calculated the odds ratio (OR) and mean difference (MD) with 95% confidence intervals (CIs) to assess the effect of hypertonic saline compared to mannitol for the management of elevated intracranial pressure in traumatic brain injury using the dichotomous or continuous method with a random or fixed-effect model.Results: Hypertonic saline had significantly lower treatment failure (OR, 0.38; 95% CI, 0.15–0.98, p = 0.04), lower intracranial pressure 30–60 mins after infusion termination (MD, −1.12; 95% CI, −2.11 to −0.12, p = 0.03), and higher cerebral perfusion pressure 30–60 mins after infusion termination (MD, 5.25; 95% CI, 3.59–6.91, p < 0.001) compared to mannitol in subjects with traumatic brain injury.However, hypertonic saline had no significant effect on favorable outcome (OR, 1.61; 95% CI, 1.01–2.58, p = 0.05), mortality (OR, 0.59; 95% CI, 0.34–1.02, p = 0.06), intracranial pressure 90–120 mins after infusion termination (MD, −0.90; 95% CI, −3.21–1.41, p = 0.45), cerebral perfusion pressure 90–120 mins after infusion termination (MD, 4.28; 95% CI, −0.16–8.72, p = 0.06), and duration of elevated intracranial pressure per day (MD, 2.20; 95% CI, −5.44–1.05, p = 0.18) compared to mannitol in subjects with traumatic brain injury.Conclusions: Hypertonic saline had significantly lower treatment failure, lower intracranial pressure 30–60 mins after infusion termination, and higher cerebral perfusion pressure 30–60 mins after infusion termination compared to mannitol in subjects with traumatic brain injury. However, hypertonic saline had no significant effect on the favorable outcome, mortality, intracranial pressure 90–120 mins after infusion termination, cerebral perfusion pressure 90–120 mins after infusion termination, and duration of elevated intracranial pressure per day compared to mannitol in subjects with traumatic brain injury. Further studies are required to validate these findings.


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Simon Hansen ◽  
Kristian Kjær Petersen ◽  
Emilie Sloth ◽  
Line Appelon Manum ◽  
Anita Kjær McDonald ◽  
...  

Abstract Objectives Exercise-induced hypoalgesia (EIH) is a decrease in the pain sensitivity after exercise. Individuals with chronic pain show less EIH after one exercise session compared with pain-free individuals possibly due to pain in exercising muscles. The primary aim of this randomized controlled cross-over study was to compare the EIH response at the exercising thigh muscle following exercises performed with painful vs. non-painful muscles. Secondary aims were to explore if a reduced EIH response was confined to the painful muscle, and whether the muscle pain intensity and the EIH responses were negatively associated. Methods In two sessions, 34 pain-free participants received a painful (hypertonic saline, 5.8%) injection and a control (isotonic saline, 0.9%) injection in the right thigh muscle before performing a 3 min isometric wall squat exercise. Pressure pain thresholds (PPTs) were assessed at both thighs and the left neck/shoulder at baseline, after injections and after exercise. Pain intensities in the thighs were rated on numerical rating scales (NRS: 0–10). Results Hypertonic saline induced moderate thigh pain at rest (NRS: 4.6 ± 2.1) compared to the control injection (NRS: 0.3 ± 0.4; p<0.001). EIH at the thighs and neck/shoulder were not different between sessions (Injected thigh: 0 kPa; 95% CI: −51 to 52; Contralateral thigh: −6 kPa; 95% CI: −42 to 30; neck/shoulder: 19 kPa; 95% CI: −6 to 44). No significant associations between pain intensity ratings immediately after the Painful injection and EIH responses at any assessment sites were found (right thigh: β=0.08, 95% CI: −12.95 to 20.64, p=0.64, left thigh: β=−0.33, 95% CI: −27.86 to 0.44, p=0.06; neck/shoulder: β=−0.18, 95% CI: −15.11 to 4.96, p=0.31). Conclusions Pain in the area of an exercising muscle did not reduce local or systemic EIH responses. Trial registration number NCT04354948.


2021 ◽  
Vol 50 (1) ◽  
pp. 289-289
Author(s):  
Peter Moran ◽  
Ayesha Mukhtar ◽  
Prem Kandiah ◽  
Alley Killian ◽  
Jolie Gallagher

2021 ◽  
Vol 50 (1) ◽  
pp. 794-794
Author(s):  
Austin Weiss ◽  
Helen Harvey ◽  
Jennifer Foley ◽  
Nicole Coufal

Author(s):  
Lucía Álvarez-Santamarta ◽  
José J. Bande ◽  
Elena Astudillo ◽  
Manuel Gorostidi ◽  
Carmen Díaz-Corte

2021 ◽  
Author(s):  
Adam Li ◽  
Clarissa Ting Li

SARS-CoV-2 enters into the human body mainly through the nasal epithelial cells. Cell entry of SARS-CoV-2 needs to be pre-activated by S1/S2 boundary furin motif cleavage by furin and/or relevant proteases. It is important to locally block SARS-CoV-2 S1/S2 site cleavage caused by furin and other relevant protease activity in the nasal cavity. We tested hypertonic saline and aprotinin-based blockage of SARS-CoV-2 specific furin site cleavage by furin, trypsin and nasal swab samples containing nasal proteases. Our results show that saline and aprotinin block SARS-Cov-2 specific furin site cleavage and that a saline and aprotinin combination could significantly reduce SARS-Cov-2 wild-type and P681R mutant furin site cleavage by inhibition of nasal protease activity.


Sign in / Sign up

Export Citation Format

Share Document